Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)

Anna B. Glinskii, Gennadi V. Glinsky, Hung Y. Lin, Heng Yuan Tang, Mingzeng Sun, Faith B. Davis, Mary K. Luidens, Shaker A. Mousa, Aleck H. Hercbergs, Paul J. Davis

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Tetraiodothyroacetic acid (tetrac) inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin αvβ3. Via interaction with the integrin, tetrac is also capable of inhibiting the angiogenic effects of vascular endothelial growth factor and basic fibroblast growth factor. MDA-MB-231 cells are estrogen receptor-negative human breast cancer cells shown to be responsive to tetrac in terms of decreased cell proliferation. Here we describe actions initiated at the cell surface receptor by unmodified tetrac and nanoparticulate tetrac on a panel of survival pathway genes in estrogen receptor-negative human breast cancer (MDA-MB-231) cells. Nanoparticulate tetrac is excluded from the cell interior. Expression of apoptosis inhibitors XIAP (X-linked inhibitor of apoptosis) and MCL1 (myeloid cell leukemia sequence 1) was downregulated by nanoparticulate tetrac in these breast cancer cells whereas apoptosis-promoting CASP2 and BCL2L14 were upregulated by the nanoparticulate formulation. Unmodified tetrac affected only XIAP expression. Expression of the angiogenesis inhibitor thrombospondin 1 (THBS1) gene was increased by both formulations of tetrac, as was the expression of CBY1, a nuclear inhibitor of catenin activity. the majority of differentially regulated Ras-oncogene family members were downregulated by nanoparticulate tetrac. The latter downregulated expression of epidermal growth factor receptor gene and unmodified tetrac did not. Nanoparticulate tetrac has coherent anti-cancer actions on expression of differentially-regulated genes important to survival of MDA-MB-231 cells.

Original languageEnglish
Pages (from-to)3562-3570
Number of pages9
JournalCell Cycle
Volume8
Issue number21
Publication statusPublished - Nov 1 2009
Externally publishedYes

Fingerprint

Breast Neoplasms
Gene Expression
Survival
Apoptosis
Down-Regulation
Integrins
Estrogen Receptors
Myeloid Cell Leukemia Sequence 1 Protein
tetraiodothyroacetic acid
Genes
Thrombospondin 1
erbB-1 Genes
Catenins
Angiogenesis Inhibitors
ras Genes
Cell Surface Receptors
Fibroblast Growth Factor 2
Thyroid Hormones
Vascular Endothelial Growth Factor A
Cell Proliferation

Keywords

  • Apoptosis
  • Cell survival genes
  • MDA-MB-231 cells
  • Microarray
  • Tetraiodothyroacetic acid
  • Thyroid hormone

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Biology

Cite this

Glinskii, A. B., Glinsky, G. V., Lin, H. Y., Tang, H. Y., Sun, M., Davis, F. B., ... Davis, P. J. (2009). Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle, 8(21), 3562-3570.

Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). / Glinskii, Anna B.; Glinsky, Gennadi V.; Lin, Hung Y.; Tang, Heng Yuan; Sun, Mingzeng; Davis, Faith B.; Luidens, Mary K.; Mousa, Shaker A.; Hercbergs, Aleck H.; Davis, Paul J.

In: Cell Cycle, Vol. 8, No. 21, 01.11.2009, p. 3562-3570.

Research output: Contribution to journalArticle

Glinskii, AB, Glinsky, GV, Lin, HY, Tang, HY, Sun, M, Davis, FB, Luidens, MK, Mousa, SA, Hercbergs, AH & Davis, PJ 2009, 'Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)', Cell Cycle, vol. 8, no. 21, pp. 3562-3570.
Glinskii, Anna B. ; Glinsky, Gennadi V. ; Lin, Hung Y. ; Tang, Heng Yuan ; Sun, Mingzeng ; Davis, Faith B. ; Luidens, Mary K. ; Mousa, Shaker A. ; Hercbergs, Aleck H. ; Davis, Paul J. / Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). In: Cell Cycle. 2009 ; Vol. 8, No. 21. pp. 3562-3570.
@article{1e67099fd4e042bf8180d8305aee7053,
title = "Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)",
abstract = "Tetraiodothyroacetic acid (tetrac) inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin αvβ3. Via interaction with the integrin, tetrac is also capable of inhibiting the angiogenic effects of vascular endothelial growth factor and basic fibroblast growth factor. MDA-MB-231 cells are estrogen receptor-negative human breast cancer cells shown to be responsive to tetrac in terms of decreased cell proliferation. Here we describe actions initiated at the cell surface receptor by unmodified tetrac and nanoparticulate tetrac on a panel of survival pathway genes in estrogen receptor-negative human breast cancer (MDA-MB-231) cells. Nanoparticulate tetrac is excluded from the cell interior. Expression of apoptosis inhibitors XIAP (X-linked inhibitor of apoptosis) and MCL1 (myeloid cell leukemia sequence 1) was downregulated by nanoparticulate tetrac in these breast cancer cells whereas apoptosis-promoting CASP2 and BCL2L14 were upregulated by the nanoparticulate formulation. Unmodified tetrac affected only XIAP expression. Expression of the angiogenesis inhibitor thrombospondin 1 (THBS1) gene was increased by both formulations of tetrac, as was the expression of CBY1, a nuclear inhibitor of catenin activity. the majority of differentially regulated Ras-oncogene family members were downregulated by nanoparticulate tetrac. The latter downregulated expression of epidermal growth factor receptor gene and unmodified tetrac did not. Nanoparticulate tetrac has coherent anti-cancer actions on expression of differentially-regulated genes important to survival of MDA-MB-231 cells.",
keywords = "Apoptosis, Cell survival genes, MDA-MB-231 cells, Microarray, Tetraiodothyroacetic acid, Thyroid hormone",
author = "Glinskii, {Anna B.} and Glinsky, {Gennadi V.} and Lin, {Hung Y.} and Tang, {Heng Yuan} and Mingzeng Sun and Davis, {Faith B.} and Luidens, {Mary K.} and Mousa, {Shaker A.} and Hercbergs, {Aleck H.} and Davis, {Paul J.}",
year = "2009",
month = "11",
day = "1",
language = "English",
volume = "8",
pages = "3562--3570",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "21",

}

TY - JOUR

T1 - Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)

AU - Glinskii, Anna B.

AU - Glinsky, Gennadi V.

AU - Lin, Hung Y.

AU - Tang, Heng Yuan

AU - Sun, Mingzeng

AU - Davis, Faith B.

AU - Luidens, Mary K.

AU - Mousa, Shaker A.

AU - Hercbergs, Aleck H.

AU - Davis, Paul J.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Tetraiodothyroacetic acid (tetrac) inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin αvβ3. Via interaction with the integrin, tetrac is also capable of inhibiting the angiogenic effects of vascular endothelial growth factor and basic fibroblast growth factor. MDA-MB-231 cells are estrogen receptor-negative human breast cancer cells shown to be responsive to tetrac in terms of decreased cell proliferation. Here we describe actions initiated at the cell surface receptor by unmodified tetrac and nanoparticulate tetrac on a panel of survival pathway genes in estrogen receptor-negative human breast cancer (MDA-MB-231) cells. Nanoparticulate tetrac is excluded from the cell interior. Expression of apoptosis inhibitors XIAP (X-linked inhibitor of apoptosis) and MCL1 (myeloid cell leukemia sequence 1) was downregulated by nanoparticulate tetrac in these breast cancer cells whereas apoptosis-promoting CASP2 and BCL2L14 were upregulated by the nanoparticulate formulation. Unmodified tetrac affected only XIAP expression. Expression of the angiogenesis inhibitor thrombospondin 1 (THBS1) gene was increased by both formulations of tetrac, as was the expression of CBY1, a nuclear inhibitor of catenin activity. the majority of differentially regulated Ras-oncogene family members were downregulated by nanoparticulate tetrac. The latter downregulated expression of epidermal growth factor receptor gene and unmodified tetrac did not. Nanoparticulate tetrac has coherent anti-cancer actions on expression of differentially-regulated genes important to survival of MDA-MB-231 cells.

AB - Tetraiodothyroacetic acid (tetrac) inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin αvβ3. Via interaction with the integrin, tetrac is also capable of inhibiting the angiogenic effects of vascular endothelial growth factor and basic fibroblast growth factor. MDA-MB-231 cells are estrogen receptor-negative human breast cancer cells shown to be responsive to tetrac in terms of decreased cell proliferation. Here we describe actions initiated at the cell surface receptor by unmodified tetrac and nanoparticulate tetrac on a panel of survival pathway genes in estrogen receptor-negative human breast cancer (MDA-MB-231) cells. Nanoparticulate tetrac is excluded from the cell interior. Expression of apoptosis inhibitors XIAP (X-linked inhibitor of apoptosis) and MCL1 (myeloid cell leukemia sequence 1) was downregulated by nanoparticulate tetrac in these breast cancer cells whereas apoptosis-promoting CASP2 and BCL2L14 were upregulated by the nanoparticulate formulation. Unmodified tetrac affected only XIAP expression. Expression of the angiogenesis inhibitor thrombospondin 1 (THBS1) gene was increased by both formulations of tetrac, as was the expression of CBY1, a nuclear inhibitor of catenin activity. the majority of differentially regulated Ras-oncogene family members were downregulated by nanoparticulate tetrac. The latter downregulated expression of epidermal growth factor receptor gene and unmodified tetrac did not. Nanoparticulate tetrac has coherent anti-cancer actions on expression of differentially-regulated genes important to survival of MDA-MB-231 cells.

KW - Apoptosis

KW - Cell survival genes

KW - MDA-MB-231 cells

KW - Microarray

KW - Tetraiodothyroacetic acid

KW - Thyroid hormone

UR - http://www.scopus.com/inward/record.url?scp=70449718848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449718848&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:70449718848

VL - 8

SP - 3562

EP - 3570

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 21

ER -